Sarissa Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Sarissa Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-950	Closed	-$18K	–	13
2021 Q2	$18K	Hold	950	–	–	﹤0.01%	14
2021 Q1	$21K	Hold	950	–	–	﹤0.01%	14
2020 Q4	$23K	Sell	950 -1,200,050	-100%	-$39.8M	﹤0.01%	12
2020 Q3	$49.8M	Hold	1,201,000	–	–	5.86%	8
2020 Q2	$57.5M	Buy	1,201,000 +46,000	+4%	+$3.55M	6.4%	8
2020 Q1	$72.7M	Buy	1,155,000 +295,000	+34%	+$26.5M	9.28%	7
2019 Q4	$107M	Buy	860,000 +9,000	+1%	+$806K	8.85%	4
2019 Q3	$56.5M	Buy	851,000 +94,000	+12%	+$6.31M	7.08%	6
2019 Q2	$60.2M	Buy	757,000 +437,000	+137%	+$39.1M	7.51%	6
2019 Q1	$35.8M	Buy	320,000 +266,000	+493%	+$29.1M	5.39%	7
2018 Q4	$5.44M	Sell	54,000 -203,500	-79%	-$21.1M	1.21%	7
2018 Q3	$32.5M	Sell	257,500 -377,800	-59%	-$40M	7.18%	6
2018 Q2	$53.3M	Hold	635,300	–	–	10.69%	6
2018 Q1	$39.1M	Buy	635,300 +453,000	+248%	+$27.3M	9.04%	7
2017 Q4	$10.6M	Buy	+182,300	New	+$11.5M	2.73%	7

Other funds holding ICPT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

EAM

EULAV Asset Management Sarasota, Florida $3.13B AUM 23.04% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sarissa Capital Management's ICPT Position: Q3 2021 in Review

Sarissa Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2021, closing a stake of 950 shares — an estimated $18K sold.

Sarissa Capital Management first reported a position in ICPT in Q4 2017 and held it in 15 quarters. The position peaked at $107M in Q4 2019. 139 funds tracked by Wall St. Rank hold ICPT as of Q3 2021.

Sarissa Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Sarissa Capital Management sold 950 Intercept Pharmaceuticals, Inc. shares in Q3 2021, an estimated $18K.
Sarissa Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2017 and held it in 15 quarters.
Sarissa Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $107M in Q4 2019.
139 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2021.

Based on Sarissa Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.